Comparative Pharmacology
Head-to-head clinical analysis: BENYLIN versus CLARITIN REDITABS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENYLIN versus CLARITIN REDITABS.
BENYLIN vs CLARITIN REDITABS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENYLIN (diphenhydramine) is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating allergic symptoms. It also crosses the blood-brain barrier and acts as a central nervous system depressant via inhibition of histamine and acetylcholine, producing sedative, antiemetic, and antitussive effects.
Loratadine is a selective antagonist of peripheral histamine H1 receptors, reducing allergic response symptoms by inhibiting histamine release from mast cells.
Oral: 10-20 mL (25-50 mg diphenhydramine) every 4-6 hours; maximum 100 mg per day.
10 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; extended to 10-12 hours in hepatic impairment, increasing risk of accumulation.
Terminal elimination half-life: 8–28 hours (mean ~14 hours for loratadine; active metabolite desloratadine: 14–26 hours). Context: Allows once-daily dosing; half-life extended in hepatic impairment.
Renal: ~80% as unchanged drug and glucuronide conjugates; fecal/biliary: ~20%.
Renal (approximately 40% as metabolites) and fecal (approximately 40% as metabolites). Parent drug and active metabolite (desloratadine) are excreted in urine (27% total) and feces (40% total).
Category C
Category C
Antihistamine
Antihistamine